1. Tan KS. New insights on classification, identification, and clinical relevance of
Blastocystis spp. Clin Microbiol Rev 2008;21:639-665.
2. Alfellani MA, Stensvold CR, Vidal-Lapiedra A, Onuoha ES, Fagbenro-Beyioku AF, Clark CG. Variable geographic distribution of
Blastocystis subtypes and its potential implications. Acta Trop 2013;126:11-18.
3. Stark D, van Hal S, Marriott D, Ellis J, Harkness J. Irritable bowel syndrome: A review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol 2007;37:11-20.
4. Gallagher PG, Venglarcik JS 3rd.
Blastocystis hominis enteritis. Pediatr Infect Dis 1985;4:556-557.
5. Tsang TK, Levin BS, Morse SR. Terminal ileitis associated with
Blastocystis hominis infection. Am J Gastroenterol 1989;84:798-799.
6. Mirza H, Teo JD, Upcroft J, Tan KS. A rapid, high-throughput viability assay for
Blastocystis spp. reveals metronidazole resistance and extensive subtype dependent variations in drug susceptibilities. Antimicrob Agents Chemother 2011;55:637-648.
7. Stensvold CR, Smith HV, Nagel R, Olsen KE, Traub RJ. Eradication of
Blastocystis carriage with antimicrobials: reality or delusion? J Clin Gastroenterol 2010;44:85-90.
8. Tan KS, Mirza H, Teo JD, Wu B, Macary PA. Current views on the clinical relevance of
Blastocystis spp. Curr Infect Dis Rep 2010;12:28-35.
9. Johnson PJ. Metronidazole and drug resistance. Parasitology Today 1993;9:183-186.
10. Lemée V, Zaharia I, Nevez G, Rabodonirina M, Brasseur P, Ballet JJ, Favennec L. Metronidazole, albendazole susceptibility of 11 clinical isolates of
Giardia duodenalis from France. J Antimicrob Chemother 2000;46:819-821.
13. Rodríguez C, Alcudia JF, Martínez-González J, Guadall A, Raposo B, Sánchez-Gómez S, Badimon L. Statins normalize vascular lysyl oxidase down regulation induced by proatherogenic risk factors. Cardiovasc Res 2009;83:595-603.
14. Mirza H, Wu Z, Teo JD, Tan KS. Statin pleiotropy prevents rho kinase-mediated intestinal epithelial barrier compromise induced by
Blastocystis cysteine proteases. Cell Microbiol 2012;14:1474-1484.
15. Dagci H, Ustun S, Taner MS, Ersoz G, Karacasu F, Budak S. Protozoon infections and intestinal permeability. Acta Trop 2002;81:1-5.
16. Puthia MK, Sio SW, Lu J, Tan KS.
Blastocystis ratti induces contact-independent apoptosis, F-actin rearrangement, and barrier function disruption in IEC-6 cells. Infect Immun 2006;74:4114-4123.
17. Jones WR. The experimental infection of rats with
Entamoeba histolytica with a method for evaluating the anti-amoebic properties of new compounds. Ann Trop Med Parasitol 1946;40:130-140.
18. Eida OM, Hussein EM, Eida AM, El-Moamly AA, Salem AM. Evaluation of the nitric oxide activity against
B.hominis in vitro and in vivo. J Egypt Soc Parasitol 2008;38:521-536.
19. Parkar U, Traub RJ, Kumar S, Mungthin M, Vitali S, Leelayoova S, Morris K, Thompson RC. Direct characterization of
Blastocystis from feces by PCR and evidence of zoonotic potential. Parasitology 2007;134:359-367.
20. Yang LQ, Singh M, Yap EH, Ng GC, Xu HX, Sim KY. In vitro response of
Blastocystis hominis against traditional Chinese medicine. J Ethnopharmacol 1996;55:35-42.
21. Shlim DR, Hoge CW, Rajah R, Rabold JG, Echeverria P. Is
Blastocystis hominis a cause of diarrhea in travelers? A prospective controlled study in Nepal. Clin Infect Dis 1995;21:97-101.
22. Yoshikawa H, Abe N, Wu Z. PCR-based identification of zoonotic isolates of
Blastocystis from mammals and birds. Microbiology 2004;150:1147-1151.
23. Haresh K, Suresh K, Khairul Anuar A, Saminathan S. Isolate resistance of
Blastocystis hominis to metronidazole. Trop Med Int Health 1999;4:244-277.
25. Penna-Coutinho J, Cortopassi WA, Oliveira AA, França TC, Krettli AU. Antimalarial activity of potential inhibitors of
Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS One 2011;6:e21237.
26. Moe KT, Singh M, Howe J, Ho LC, Tan SW, Chen XQ, Ng GC, Yap EH. Experimental
Blastocystis hominis infection in laboratory mice. Parasitol Res 1997;83:319-325.
27. Coppens I, Bastin P, Levade T, Courtoy PJ. Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in
Trypanosoma brucei
. Mol Biochem Parasitol 1995;69:29-40.
28. Soliman MF, Ibrahim MM. Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on
Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study. Acta Trop 2005;93:1-9.
29. Cortez E, Stumbo AC, Oliveira M, Barbosa HS, Carvalho L. Statins inhibit
Toxoplasma gondii multiplication in macrophages in vitro. Int J Antimicrob Agents 2009;33:185-186.
30. Nishikawa Y, Quittnat F, Stedman TT, Voelker DR, Choi JY, Zahn M, Yang M, Pypaert M, Joiner KA, Coppens I. Host cell lipids control cholesteryl ester synthesis and storage in intracellular
Toxoplasma
. Cell Microbiol 2005;7:849-867.
31. Li ZH, Ramakrishnan S, Striepen B, Moren SN.
Toxoplasma gondii relies on Both Host and Parasite Isoprenoids and Can Be Rendered Sensitive to Atorvastatin. PLoS Pathog 2013;9:e1003665.
32. Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, Baret E, Fusaï T, Rogier C, Pradines B. Atorvastatin is a promising partner for antimalarial drugs in treatment of
Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009;53:2248-2252.
33. Taoufiq Z, Gay F, Balvanyos J, Ciceron L, Tefit M, Lechat P, Mazier D. Rho kinase inhibition in severe malaria: thwarting parasite induced collateral damage to endothelia. J Infect Dis 2008;197:1062-1073.
34. Bessoff K, Sateriale A, Lee KK, Huston CD. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block
C. parvum growth. Antimicrob Agents Chemother 2013;57:1804-1814.
35. Dinesh N, Pallerla DS, Kaur PK, Kishore Babu N, Singh S. Exploring
Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies. Microb Pathog 2014;66:14-23.
36. Kumar GA, Roy S, Jafurulla M, Mandal C, Chattopadhyay A. Statin-induced chronic cholesterol depletion inhibits
Leishmania donovani infection: Relevance of optimum host membrane cholesterol. Biochim Biophys Acta 2016;1858:2088-2096.
37. Pradines B, Torrentino-Madamet M, Fontaine A, Henry M, Baret E, Mosnier J, Briolant S, Fusai T, Rogier C. Atorvastatin is 10-fold more active in vitro than other statins against
Plasmodium falciparum
. Antimicrob Agents Chemother 2007;51:2654-2655.
40. Savini H, Souraud JB, Briolant S, Baret E, Amalvict R, Rogier C, Pradines B. Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Antimicrob Agents Chemother 2010;54:966-967.